- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07419555
Belgische Lungenfunktionsstudie (AIRCAST)
Belgische Lungenfunktionsstudie: Personalisierte longitudinale Lungenfunktionsanalyse als Marker für Krankheitsfortschritt
Currently, it remains unclear how to manage serial lung function measurements in a clinical setting. The investigators aimed to tackle this problem by developing a machine learning (ML) model that can accurately predict population and individual lung function trajectories. These predictions would enable the investigators to identify positive or negative deviations, thereby revealing unexpected disease patterns.
A prospective validation is needed that includes data on mortality, hospitalisations, emergency-room visits and patient-reported outcomes. Within this study, the goal is to validate the ML model with the data collected from this observational study.
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
The objective of this study is to explore the clinical value of models predicting longitudinal lung function patterns in individuals with chronic respiratory diseases across Belgium.
- The investigators will assess the accuracy of individualised lung function prediction models in a multicentre lung function dataset with prospective clinical and lung function follow-up.
- The investigators will evaluate important health outcomes, step-up in care, patient-reported outcomes in individuals identified with an expected and unexpected observed trajectory as compared to the predicted population and individualised trajectory.
The hypothesis is that patients with an unexpected decline in lung function will have worse health outcomes, such as a higher mortality rate and more hospitalisations, compared to patients with an expected lung function pattern. The investigators hypothesise to observe better health outcomes and lower mortality rates in patients with an unexpectedly positive lung function evolution compared to patients with an expected negative lung function pattern.
Individuals will be recruited from 4 Belgian Hospitals (UZ Leuven, UZ Antwerpen, AZ Delta, ZOL Genk). Based on the annual rate of pulmonary function testing in these hospitals, a sample size of 1.000 participants per centre is anticipated within one year of inclusions, resulting in a total sample size of 4.000 patients.
All available historical lung function data of included individuals will be retrieved from the individuals medical file. Additionally, the individual will be prospectively followed for 2 years where all lung function data will be collected.
Studientyp
Einschreibung (Geschätzt)
Kontakte und Standorte
Studienkontakt
- Name: Marieke Wuyts
- Telefonnummer: 016 34 31 59
- E-Mail: marieke.wuyts@kuleuven.be
Studienorte
-
-
-
Edegem, Belgien, 2650
- Rekrutierung
- UZ Antwerpen
-
Kontakt:
- Therese Lapperre
- Telefonnummer: 0032 3 821 5089
- E-Mail: therese.lapperre@uza.be
-
Hauptermittler:
- Therese Lapperre
-
Unterermittler:
- Kevin De Soomer
-
Genk, Belgien, 3600
- Rekrutierung
- Ziekenhuis Oost-Limburg
-
Kontakt:
- David Ruttens
- Telefonnummer: 0032 89 80 52 00
- E-Mail: david.ruttens@zol.be
-
Hauptermittler:
- David Ruttens
-
Unterermittler:
- Maarten Criel
-
Ghent, Belgien
- Rekrutierung
- UZ Gent
-
Hauptermittler:
- Eric Derom
-
Kontakt:
- Eric Derom
- Telefonnummer: 0032 9 332 23 42
- E-Mail: Eric.Derom@uzgent.be
-
Unterermittler:
- Lies Lahousse
-
Leuven, Belgien, 3000
- Rekrutierung
- UZ Leuven
-
Hauptermittler:
- Wim Janssens
-
Kontakt:
- Marieke Wuyts
- Telefonnummer: 016 34 31 59
- E-Mail: marieke.wuyts@kuleuvne.be
-
Roeselare, Belgien, 8800
- Rekrutierung
- AZ Delta
-
Hauptermittler:
- Ingel Demedts
-
Kontakt:
- Ingel Demedts
- Telefonnummer: 0032 51 23 41 16
- E-Mail: ingel.demedts@azdelta.be
-
Unterermittler:
- Bernard Bouckaert
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Chronic respiratory diseases
Beschreibung
Inclusion Criteria:
- Above 18 years old
- Diagnosed with a chronic respiratory disease and followed up in one of the participating Belgian hospitals
- Performed a complete lung function test (spirometry, body plethysmography and diffusion capacity) at baseline
- Have at least 3 historical spirometry measurements over a minimal time window of 2 years prior to inclusion
- Planned routine follow-up within standard clinical care in one of the participating hospitals
Exclusion Criteria:
- Patients who have had a lung transplantation
- Patients not being able to give consent to participate
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: COHORT
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Accuracy of lung function predictions (FEV1)
Zeitfenster: at 1 and 2-year follow-up
|
Proportion of correct and incorrect FEV1 predictions compared to the observed measure |
at 1 and 2-year follow-up
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Differences in clinical outcomes between correct and incorrect lung function predictions (FEV1)
Zeitfenster: at 1 and 2-year follow-up
|
Differences between patients with correct and incorrect individual lung function predictions for FEV1 on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care |
at 1 and 2-year follow-up
|
|
Accuracy of lung function predictions
Zeitfenster: at 1 and 2-year follow-up
|
Proportion of correct and incorrect lung function predictions (FVC, TLC, RV/TLC, DLCO) compared to the observed measure |
at 1 and 2-year follow-up
|
|
Differences in clinical outcomes between correct and incorrect lung function predictions
Zeitfenster: at 1 and 2-year follow-up
|
Differences between patients with correct and incorrect individual lung function predictions for FVC, TLC, RV/TLC, DLCO on clinical endpoints (such as mortality, hospitalisations, frailty, health status and step-up in care) |
at 1 and 2-year follow-up
|
|
Identifying the minimal needed to make predictions
Zeitfenster: after 2 years
|
Minimal number of tests/length of follow-up required for optimal predictions |
after 2 years
|
|
Performance of ML-based predictions compared to linear regression analysis
Zeitfenster: at 1 and 2-year follow-up
|
Comparison of the ML-based predictions for individual and population lung function changes with predictions based on linear regression on individual historical data |
at 1 and 2-year follow-up
|
|
Overall description of population
Zeitfenster: baseline, 1 and 2-year follow-up
|
Sociodemographic information, health status, comorbidities, frailty, disease labels, interventions and prognosis of individuals with a chronic respiratory disease |
baseline, 1 and 2-year follow-up
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Wim Janssens, UZ/KU Leuven
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- S70923
- C2M25045 (Andere Zuschuss-/Finanzierungsnummer: Internal funding KULeuven)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .